{
    "doi": "https://doi.org/10.1182/blood.V120.21.4482.4482",
    "article_title": "Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning ",
    "article_date": "November 16, 2012",
    "session_type": "Clinical Allogeneic and Autologous Transplantation - Results Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution",
    "abstract_text": "Abstract 4482 Introduction: Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning (RIC) including radioimmunotherapy (RIT) with yttrium-90 ibritumomab tiuxetan is a potential salvage treatment for patients with advanced high-risk B-cell lymphoma. The influence of RIT combined with RIC on immune reconstitution after allogeneic HCT has not been evaluated. Methods: We compared data on immune reconstitution of 14 patients receiving allogeneic HCT after RIT-RIC at our institution from 2006 to 2008. Yttrium-90 ibritumomab tiuxetan as RIT and RIC with either fludarabine (30 mg/m 2 , day \u22128 to \u22124)/melphalan (140 mg/m 2 , day \u22123)/alemtuzumab (20 mg for related donors and 30 mg for unrelated donors, day \u22123 and \u22122) (n=7, FLU/MEL/AL-RIT group) or fludarabine (30 mg/m 2 , day \u22124 to \u22122)/2 Gy total body irradiation (day 0) (n=7, FLU/TBI-RIT group) were used. Immunosuppression consisted of cyclosporine A alone (FLU/MEL/AL-RIT group) or cyclosporine A combined with mycophenolate mofetil (FLU/TBI-RIT group). The results were compared to 14 patients in a concurrent control group with similar conditioning regimens without RIT (n=7, FLU/MEL (without alemtuzumab); n=7, FLU/TBI). Differences in engraftment and immune reconstitution were evaluated. Results: Diagnoses in the RIT groups were high-grade NHL (n=6), low-grade NHL (n=6) and CLL (n=2). In the control groups diagnoses were high-grade NHL (n=4), acute leukemia (n=6), MDS (n=1), multiple myeloma (n=1), Hodgkin's lymphoma (n=1) and CLL (n=1). Neutrophil engraftment (>500/\u03bcl) was observed after a median of 20 days (range 13\u201326) in the FLU/MEL/AL-RIT-group compared to 15 days (range 11\u201321) in the control group ( p =0.11). After a median of 13 days (range 7\u201317) and 12 days (range 8\u201327) neutrophil engraftment was noted in the FLU/TBI-RIT group and control group, respectively ( p =0.40). Median time to thrombocyte engraftment (>20,000/\u03bcl) was 11 days (range 8\u201342) in the FLU/MEL/AL-RIT-group and 21 days (range 5\u201329) in the control group ( p =0.81). After a median of 10 days (range 7\u201316) and 11 days (range 10\u201335) thrombocyte engraftment was noted in the FLU/TBI-RIT group and control group, respectively ( p =0.23). Immune reconstitution in the four groups is shown in Table 1 :  . . FLU/MEL/AL-RIT . FLU/MEL . . FLU/TBI-RIT . FLU/TBI . . . day . cells/\u03bcl median (range) . p = . cells/\u03bcl median (range) . p = . CD3+ T-cells +100 65 (38\u2013201) 239 (92\u2013353) 0.06 405 (247\u20137452) 483 (301\u2013909) 0.27  +500 820 (117\u2013994) 1409 (422\u20132532) 0.13 465 (261\u20134481) 536 (10\u20132553) 0.49 CD3+4+ T-cells +100 57 (22\u201381) 73 (35\u201399) 0.36 189 (85\u20131105) 251 (27\u2013337) 0.32  +500 90 (27\u2013151) 184 (72\u2013366) 0.22 102 (42\u2013951) 186 (3\u2013257) 0.26 CD3+8+ T-cells +100 13 (4\u2013126) 139 (33\u2013218) 0.08 214 (84\u20136181) 251 (137\u2013539) 0.27  +500 240 (13\u2013271) 732 (72\u20131469) 0.09 100 (35\u20132917) 215 (2\u20132062) 0.67 CD19+ B-cells +100 0 (0\u20131) 9 (0\u2013190) 0.20 2 (0\u201346) 45 (4\u2013155) 0.07  +500 56 (3\u2013891) 174 (1\u2013520) 0.65 140 (8\u2013440) 83 (5\u2013851) 0.60 CD16+56+ NK-cells +100 60 (39\u20131170) 176 (112\u20131199) 0.80 153 (59\u2013631) 209 (39\u2013435) 1.00  +500 303 (77\u2013837) 275 (46\u2013676) 0.79 269 (58\u20132102) 81 (2\u2013214) 0.25 . . FLU/MEL/AL-RIT . FLU/MEL . . FLU/TBI-RIT . FLU/TBI . . . day . cells/\u03bcl median (range) . p = . cells/\u03bcl median (range) . p = . CD3+ T-cells +100 65 (38\u2013201) 239 (92\u2013353) 0.06 405 (247\u20137452) 483 (301\u2013909) 0.27  +500 820 (117\u2013994) 1409 (422\u20132532) 0.13 465 (261\u20134481) 536 (10\u20132553) 0.49 CD3+4+ T-cells +100 57 (22\u201381) 73 (35\u201399) 0.36 189 (85\u20131105) 251 (27\u2013337) 0.32  +500 90 (27\u2013151) 184 (72\u2013366) 0.22 102 (42\u2013951) 186 (3\u2013257) 0.26 CD3+8+ T-cells +100 13 (4\u2013126) 139 (33\u2013218) 0.08 214 (84\u20136181) 251 (137\u2013539) 0.27  +500 240 (13\u2013271) 732 (72\u20131469) 0.09 100 (35\u20132917) 215 (2\u20132062) 0.67 CD19+ B-cells +100 0 (0\u20131) 9 (0\u2013190) 0.20 2 (0\u201346) 45 (4\u2013155) 0.07  +500 56 (3\u2013891) 174 (1\u2013520) 0.65 140 (8\u2013440) 83 (5\u2013851) 0.60 CD16+56+ NK-cells +100 60 (39\u20131170) 176 (112\u20131199) 0.80 153 (59\u2013631) 209 (39\u2013435) 1.00  +500 303 (77\u2013837) 275 (46\u2013676) 0.79 269 (58\u20132102) 81 (2\u2013214) 0.25 View Large Regeneration of CD3+8+ T-cells on day +100 and day +500 was significantly ( p <0.10) reduced in the FLU/MEL/AL-RIT group compared to the FLU/MEL control group ( p =0.08 and p =0.09) while no difference was observed between the FLU/TBI-RIT and the FLU/TBI group. No significant long-term difference in recovery of the CD19+ B-cells was observed although early B-cell levels on day +100 were reduced in the RIT groups. Conclusion: Not the use of yttrium-90 ibritumomab tiuxetan alone but its combination with alemtuzumab leads to a significantly slower immune reconstitution after allogeneic HCT. Disclosures: Off Label Use: Off-label conditioning regimen.",
    "topics": [
        "conditioning (psychology)",
        "hematopoietic stem cell transplantation",
        "ibritumomab tiuxetan",
        "immune reconstitution",
        "yttrium",
        "alemtuzumab",
        "allogeneic hematopoietic stem cell transplant",
        "yttrium-90-ibritumomab tiuxetan",
        "cyclosporine",
        "fludarabine"
    ],
    "author_names": [
        "Dominik Schneidawind, MD",
        "Sebastian Jendryssek",
        "Birgit Federmann, MD",
        "Christoph Faul, MD",
        "Wichard Vogel, MD",
        "Lothar Kanz, MD",
        "Wolfgang A Bethge, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Dominik Schneidawind, MD",
            "author_affiliations": [
                "Hematology & Oncology, Department of Medicine, University Hospital Tuebingen, Tuebingen, Germany"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Sebastian Jendryssek",
            "author_affiliations": [
                "Hematology & Oncology, Department of Medicine, University Hospital Tuebingen, Tuebingen, Germany"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Birgit Federmann, MD",
            "author_affiliations": [
                "Hematology & Oncology, Department of Medicine, University Hospital Tuebingen, Tuebingen, Germany"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Christoph Faul, MD",
            "author_affiliations": [
                "Hematology & Oncology, Department of Medicine, University Hospital Tuebingen, Tuebingen, Germany"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Wichard Vogel, MD",
            "author_affiliations": [
                "Hematology & Oncology, Department of Medicine, University Hospital Tuebingen, Tuebingen, Germany"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lothar Kanz, MD",
            "author_affiliations": [
                "Hematology & Oncology, Department of Medicine, University Hospital Tuebingen, Tuebingen, Germany"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Wolfgang A Bethge, MD",
            "author_affiliations": [
                "Hematology & Oncology, Department of Medicine, University Hospital Tuebingen, Tuebingen, Germany"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-21T18:38:43",
    "is_scraped": "1"
}